Pregabalin for the treatment of Fibromyalgia syndrome: Results of a randomized, double-blind, placebo-controlled trial

Arthritis and Rheumatism

Volumn 52, Issue 4, 2005, Pages 1264-1273

  Crofford, Leslie J ^a,b   Rowbotham, Michael C ^c   Mease, Philip J ^d   Russell, I Jon ^e   Dworkin, Robert H ^f   Corbin, Ann E ^g   Young Jr , James P ^g   LaMoreaux, Linda K ^g   Martin, Susan A ^g   Sharma, Uma ^g  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SWEDISH MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^g PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PREGABALIN;

ACCIDENT; ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVELOPMENTAL COORDINATION DISORDER; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EUPHORIA; FATIGUE; FEMALE; FIBROMYALGIA; FLU LIKE SYNDROME; HEADACHE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN; PAIN ASSESSMENT; PAIN THRESHOLD; PERIPHERAL EDEMA; PHARYNGITIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINUSITIS; SOMNOLENCE; TREATMENT WITHDRAWAL; WEIGHT GAIN; XEROSTOMIA;

ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FATIGUE; FIBROMYALGIA; GAMMA-AMINOBUTYRIC ACID; PAIN; PAIN MEASUREMENT; PLACEBOS; QUALITY OF LIFE; SLEEP DISORDERS; TREATMENT OUTCOME;

EID: 20244389715     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20983     Document Type: Article

References (43)

1. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38:19-28.
2. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-72.
3. Crofford L, Clauw D. Fibromyalgia: where are we a decade after the American College of Rheumatology classification criteria were developed? [editorial]. Arthritis Rheum 2002;46:1136-8.
4. Clauw DJ, Crofford LJ. Chronic widespread pain and fibromyalgia: what we know, and what we need to know. Best Pract Res Clin Rheumatol 2003;17:685-701.
5. Goldenberg DL. Fibromyalgia, chronic fatigue syndrome, and myofascial pain syndrome. Curr Opin Rheumatol 1993;5:199-208.
6. Epstein SA, Kay G, Clauw D, Heaton R, Klein D, Krupp L, et al. Psychiatric disorders in patients with fibromyalgia: a multicenter investigation. Psychosomatics 1999;40:57-63.
7. McBeth J, Silman AJ. The role of psychiatric disorders in fibromyalgia. Curr Opin Rheumatol 2001;3:157-64.
8. Richards S, Cleare A. Treating fibromyalgia. Rheumatology (Oxford) 2000;39:343-6.
9. Barkhuizen A. Rational and targeted pharmacologic treatment of fibromyalgia. Rheum Dis Clin North Am 2002;28:261-90.
10. 2δ subunit of a calcium channel. J Biol Chem 1996;271:5768-76.
11. Marais E, Klugbauer N, Hofmann F. Calcium channel α(2)δ subunits: structure and gabapentin binding. Mol Pharmacol 2001;59:1243-8.
12. Qin N, Yagel S, Momplaisir ML, Codd EE, D'Andrea MR. Molecular cloning and characterization of the human voltage-gated calcium channel α2δ-4 subunit. Mol Pharmacol 2002;62:485-96.
13. Arikkath J, Campbell KP. Auxiliary subunits: essential components of the voltage-gated calcium channel complex. Curr Opin Neurobiol 2003;13:298-307.
14. Dubel SJ, Altier C, Chaumont S, Lory P, Bourinet E, Nargeot J. Plasma membrane expression of T-type calcium channel α(1) subunits is modulated by high voltage-activated auxiliary subunits. J Biol Chem 2004;279:29263-9.
15. Fink K, Dooley DJ, Meder WP, Suman-Chauhan N, Duffy S, Clusmann H, et al. Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 2002;42:229-36.
16. Dooley DJ, Donovan CM, Pugsley TA. Stimulus-dependent modulation of [3H]-norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther 2000;295:1086-93.
17. Dooley DJ, Mieske CA, Borosky SA. Inhibition of K(+)-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci Lett 2000;280:107-10.
18. (3)H]glutamate from rat caudal trigeminal nucleus slices. Pain 2001;93:191-6.
19. Taylor CP. Meeting report: the biology and pharmacology of calcium channel proteins (Pfizer satellite symposium to the 2003 Society for Neuroscience Meeting). CNS Drug Rev 2004;10:159-64.
20. Taylor CP. Gabapentin: mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press; 1995. p. 829-41.
21. Errante LD, Petroff OA. Acute effects of gabapentin and pregabalin on rat forebrain cellular GABA, glutamate, and glutamine concentrations. Seizure 2003;12:300-6.
22. Randinitis EJ, Posvar EL, Alvey CW, Sedman AJ, Cook JA, Bockbrader HN. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol 2003;43:277-83.
23. Corrigan BW, Pool WF, Posvar EL, Strand JC, Alvey CS, Radulovic LL, et al. Metabolic disposition of pregabalin in healthy volunteers [abstract]. Clin Pharmacol Ther 2001;69:P18.
24. Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 2004;63:2104-10.
25. Rosenstock J, Tuchman L, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004;110:628-38.
26. Dworkin RH, Corbin AE, Young JP, Sharma U, LaMoreaux L, Bockbrader H, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2003;60:1274-83.
27. Melzack R. The short-form McGill Pain Questionnaire. Pain 1987;30:191-7.
28. Hays RD, Stewart AL. Sleep measures. In: Stewart AL, Ware JEJ, editors. Measuring functioning and well-being. Durham (NC): Duke University Press; 1992. p. 232-59.
29. Belza B, Henke C, Epstein W, Gilliss C. Correlates of fatigue in older adults with rheumatoid arthritis. Nurs Res 1993;42:93-9.
30. Zigmond A, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-70.
31. Ware JE, Sherbourne CD. The MOS 36-Item Short Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
32. Okifuji A, Turk DC, Sinclair JD, Starz TW, Marcus DA. A standardized manual tender point survey. I. Development and determination of a threshold point for the identification of positive tender points in fibromyalgia syndrome. J Rheumatol 1997;24:377-83.
33. Coding symbols for a thesaurus of adverse reaction terms (COSTART). 4th ed. Washington (DC): Department of Health and Human Services, US Food and Drug Administration; 1996.
34. Berry D. Statistical methodology in the pharmaceutical sciences. New York: Marcel Dekker; 1990.
35. SAS Institute, Inc. SAS/STAT users guide. Version 6.4th ed. Cary (NC): SAS Institute, Inc.; 1989.
36. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800-2.
37. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-58.
38. Bennett RM, Kamin M, Karim R, Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med 2003;114:537-45.
39. Hudson JI, Pope HG. The relationship between fibromyalgia and major depressive disorder. Rheum Dis Clin North Am 1996;22:285-303.
40. Wolfe F, Hawley DJ, Wilson K. The prevalence and meaning of fatigue in rheumatic disease. J Rheumatol 1996;23:1407-17.
41. Wolfe F. Fibromyalgia: the clinical syndrome. Rheum Dis Clin North Am 1989;15:1-18.
42. Feltner DE, Crockatt JG, Dubovsky SJ, Cohn CK, Shrivastava RK, Targum SD, et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003;23:240-9.
43. Pande AC, Crockatt JG, Feltner DE, Janney CA, Smith WT, Weisler R, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 2003;160:533-40.